ArticleAmerican journal of epidemiology2026
Comparison of disease risk score methods to study treatment effect heterogeneity: a simulation study.
Article in American journal of epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Estimating treatment effects across disease risk scores (DRSs) is a common approach for assessing treatment effect heterogeneity in randomized trials. When external models are unavailable, the optimal approach for internally fitting the DRS model remains uncertain. This simulation study compares 3 internal derivation approaches, evaluating bias of estimated treatment effects within DRS-defined strata. We simulated trials under varying treatment effects (odds ratios [OR] of 1, 0.8, and 0.5) and treatment-covariate interactions. We fit DRS models on (1) a controls-only method, (2) the full sample ignoring treatment assignment, and (3) a random split-sample method of 50% of the controls, who were removed from the second stage of analysis. Additional simulations varied outcome incidence, sample size, randomization ratio, and the true DRS C-statistic. Bias decreased with the split-sample method (overall percent bias [OPB] 7.7% for OR = 0.8 with interactions) compared to the controls-only (OPB = 15.6%) and full-sample methods (OPB = 22.1%). Bias decreased more with the split-sample method than with controls-only and full-sample methods with larger sample sizes, higher outcome incidence, greater treated-to-control ratios, and larger C-statistics. These findings suggest split-sample methods may be the preferred approach to estimate treatment effect heterogeneity by the DRS in trials with sufficient data to support stable prediction modeling.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.